Viralgen Capacity Update October 2024: Cell & Gene Therapy

At Viralgen, we take pride in being recognized as a global leader in rAAV-based gene therapy manufacturing, dedicating ourselves entirely to AAV every single day. As an independently operated CDMO and a subsidiary of AskBio, we provide scalable cGMP rAAV gene therapy manufacturing that grows alongside our clients’ needs—from initial construct optimization and feasibility studies to large-scale commercial production.

Our company was built on a foundation of pioneering AAV science, and today, we’re home to the world’s largest manufacturing capacity dedicated solely to AAV. Our mission is clear: to advance therapies that bring patients with genetic diseases closer to life-changing—and often life-saving—treatment options.